The Stock
Trading Information
Lipigon Pharmaceuticals AB is publicly traded on the Nasdaq First North Growth Market. The company has issued shares under a single class of stock, with the stock symbol LPGO and ISIN code SE0015382072.
Top Shareholders
Development of Share Capital
On June 30, 2024, the total number of shares amounted to 605,933,743. The share capital amounted to 2.396,467 SEK. All shares have one voting right.
| Date | Transaction | Number of Common Shares | Increase in Share Capital | Invested Amount (SEK) |
|---|---|---|---|---|
| 2010-06-07 | Formation | 50 000 | 50 000 | 50 000 |
| 2016-02-04 | Share Issuance | 3 000 | 53 000 | 3 000 |
| 2016-05-12 | Share Issuance | 5 301 | 58 301 | 503 505 |
| 2016-09-06 | Share Issuance | 5 301 | 63 602 | 503 595 |
| 2016-12-19 | Share Issuance | 10 600 | 74 202 | 500 320 |
| 2017-02-01 | Share Issuance | 13 144 | 87 346 | 3 100 012 |
| 2018-01-19 | Share Issuance | 9 000 | 96 346 | 1 800 000 |
| 2018-06-18 | Share Issuance | 8 875 | 105 221 | 1 775 000 |
| 2019-05-08 | Share Issuance | 28 059 | 133 280 | 7 996 815 |
| 2020-07-07 | Share Issuance | 88 572 | 221 852 | 16 651 536 |
| 2020-08-28 | Split 1:20 | 4 215 188 | 221 852 | - |
| 2020-08-28 | Fund Issuance | - | 500 000 | - |
| 2020-12-02 | Share Issuance | 295 858 | 33 339 | 3 000 000 |
| 2021-02-23 | Share Issuance | 5 000 000 | 563 439 | 55 991 872 |
| 2022-06-21 | Share Issuance | 10 511 526 | 1 184 519 | 22 599 781 |
| 2023-04-19 | Share Issuance | 58 686 425 | 6 613 237 | 28 810 658 |
| 2023-05-04 | Share Issuance | 1 084 797 | 122 243 | 532 554 |
| 2023-12-20 | Share Issuance | 46 406 635 | 5 229 445 | 13 921 991 |
| 2024-06-17 | Share Issuance | 21 908 237 | 2 468 783 | 4 381 647 |
| 2024-06-17 | Reduction of share capital | - | -16 128 359 | - |
| 2025-06-13 | Share Issuance | 415 325 442 | 1 642 611 | 37 379 290 |
| 2025-06-13 | Share Issuance | 42 277 783 | 167 209 | 3 805 000 |
| Total | 605 933 743 | 2 396 467 | 203 306 577 |
Subscription Warrant Program
Below is a summary of the company's warrant program as of June 30, 2024.
| Program | Holders | Number of Warrants | Exercise Price | Value per Allocated Warrant | Volatility, % | Risk-free Interest Rate, % | Subscription Right per Option | Subscription (year) |
|---|---|---|---|---|---|---|---|---|
| Warrants 2023/2027* | Employees and other key persons | 4 834 858 | 0,78 | 0,07 | 58,9 | -0,23 | 1,05 | Sep 2026 - feb 2027 |
| Warrants 2023/2027* | Employees and other key persons | 2 009 286 | 0,78 | 0,06 | 58,9 | -0,23 | 1,05 | Sep 2026 - feb 2027 |
| Warrants 2025/2028 | Employees and other key persons | 12 000 000 | 0,30 | 0,04 | 67,6 | -0,19 | 1 | Jul 2028 |
| Total | 7 380 000 | - | - | - | - | - | - |
* Recalculated following the issuance of shares May 2025
Information about Nasdaq First North Growth Market
Nasdaq First North Growth Market is a registered SME marketplace for growth companies, following the Directive on Markets in Financial Instruments (EU 2014/65) implemented in the national legislation of Denmark, Finland, and Sweden. The marketplace is part of the Nasdaq Group. Issuers on Nasdaq First North Growth Market are not subject to the regulations that apply to issuers whose shares are listed on a regulated market, as defined in EU legislation (and implemented in national legislation). Instead, they are subject to less extensive rules and regulations tailored to smaller growth companies. The risk of investing in an issuer on Nasdaq First North Growth Market may, therefore, be higher than investing in an issuer listed on a regulated market. All issuers with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors compliance with the rules. Nasdaq approves issuers' applications for admission to trading.